Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of the best biotech stocks to buy according to Wall Street analysts. On November 20, H.C. Wainwright reaffirmed its Buy rating and $102 price target on Viking Therapeutics, Inc. (NASDAQ:VKTX) after the company finished enrollment ahead of schedule in its Phase 3 VANQUISH-1 obesity study, bringing in 4,650 adults instead of the planned 4,500. The trial includes people with obesity or overweight and related health conditions, marking an important step forward fo ...